Frost & Sullivan releases the 'White Paper on the Development of China's Oncolytic Virus Industry'

China's gene therapy development is in its early stages and has become a hot investment area in recent years. Among them, oncolytic virus therapy has gradually become the focus of investment attention. Due to the continuous growth in the number of malignant tumor cases globally and in China, with lung cancer, breast cancer, gastric cancer, colorectal cancer, etc., being the main types of diseases, there are a large number of potential patients for oncolytic virus therapy. With technological maturity, expanded indications, and advancement in clinical trials, there is huge commercial growth potential for oncolytic virus therapy in the future. Frost & Sullivan released the 'White Paper on the Development of Oncolytic Virus Industry in China', analyzing the current industry development status, characteristics, treatment areas, driving factors, and development trends of oncolytic viruses (OV) in China, focusing on the competitive market situation in the Chinese oncolytic virus industry, and reflecting the differentiated competitive advantages of leading enterprises in this market.